| 12/12/2024 12:30 |
PPMX-T003: Announcement on Extension of Investigator-led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL) |
| 12/10/2024 15:30 |
Announcement of Presentation of PPMX-T003 Phase I of Polycythemia Vera at 66th ASH Annual Meeting and Exposition |
| 11/18/2024 16:05 |
Presentation Material for FY2025/3 First Half Business Results |
| 11/14/2024 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 11/14/2024 15:30 |
Non-consolidated Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2025 |
| 11/11/2024 15:30 |
Announcement of Sales Launch of New Antibody/Reagent |
| 11/06/2024 11:30 |
Announcement of Presentation of PPMX-T003 Phase I at 66th ASH Annual Meeting and Exposition |
| 10/21/2024 15:00 |
Perseus Proteomics and UBE Sign a Collaborative Research Agreement on Antibody-Drug Conjugates (ADC) |
| 10/04/2024 15:05 |
Perseus Proteomics Participating in Japan Healthcare Venture Summit 2024 |
| 09/30/2024 15:05 |
Announcement of Abstract of PPMX-T002 Presentation at EANM'24 Annual Congress |
| 09/27/2024 16:00 |
PPMX-T003: Announcement on Registration of Patent Jointly Filed with Juntendo University |
| 08/26/2024 15:05 |
(Amendments) Amendments to "Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025" |
| 08/14/2024 15:05 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 08/14/2024 15:05 |
Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025 |
| 08/02/2024 15:05 |
Announcement of Agreement of Joint Research on Multispecific Antibodies with Yamagata University, Osaka Metropolitan University, and Tokyo University |
| 07/19/2024 16:30 |
Announcement of Acceptance of PPMX-T002 Research Results Presentation at EANM'24 Annual Congress |
| 07/16/2024 13:00 |
Announcement of Presentation of PPMX-T003 Phase I Interim Report at the 14th JSH International Symposium 2024 |
| 06/28/2024 15:05 |
PPMX-T003: Announcement on the End of Phase I Clinical Trial for Polycythemia Vera (PV) |
| 06/28/2024 14:10 |
PPMX-T003: Announcement of Publication of Paper Co-authored by Osaka University and Perseus Proteomics Related to ANKL Therapy |
| 06/17/2024 16:05 |
Announcement of Acceptance of Presentation of PPMX-T003 Phase I Interim Report at the 14th JSH International Symposium 2024 |
| 06/13/2024 08:00 |
PPMX-T004 Joint Research Results Presented at 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) |
| 05/17/2024 16:05 |
Presentation Material for FY2023 Business Results |
| 05/15/2024 15:05 |
Announcement of Presentation of Aggressive NK-cell Leukemia (ANKL) at EHA*2024 Hybrid Congress |
| 05/15/2024 15:05 |
Notice on Booking of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 05/15/2024 15:05 |
Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2024 |
| 05/10/2024 15:05 |
PPMX-T003: Announcement on Delay in the End of Phase I Clinical Trial for Polycythemia Vera (PV) |
| 03/22/2024 15:05 |
Announcement of Selection for Research as Practical Research for Innovative Cancer Control Program by AMED |
| 03/08/2024 17:15 |
Notice on Change of a Major Shareholder |
| 03/05/2024 19:45 |
Adoption as Tokyo Strategic Innovation Promotion Program by Tokyo Metropolitan Small and Medium Enterprise Support Center |
| 02/14/2024 15:05 |
Notice on Booking of Non-operating Income and Extraordinary Losses |
| 02/14/2024 15:05 |
Non-consolidated Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024 |
| 02/02/2024 15:05 |
PPMX-T003: Announcement on Delay in the End of Phase I Clinical Trial for Polycythemia Vera (PV) |
